Date: 2014-12-08
Type of information: Presentation of results at a congress
phase: 1
Announcement: presentation of results at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9 in San Francisco, CA
Company: Juno Therapeutics (USA - WA)
Product: JCAR015
Action
mechanism: cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy. JCAR015 is based on chimeric antigen receptor (CAR) technology. T cells are removed from blood, transduced with retroviral vector containing a chimeric antigen receptor directed against CD19, and then put back in the body. This gene will produce proteins in the T cells that help the T cells recognize the leukemia cells and possibly kill them.
Disease: non-Hodgkin’s lymphoma (NHL)
Therapeutic area: Cancer - Oncology
Country: USA
Trial
details: This trial is a Phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor (CAR) modified T-cells directed against CD19+ B-cells for relapsed and refractory aggressive B cell non-Hodgkin lymphoma. (NCT01840566)
Latest
news: * On December 8, 2014, Juno Therapeutics announced that clinical data from its most advanced chimeric antigen receptor (CAR) product candidates, JCAR015 , demonstrated encouraging evidence of clinical responses in non-Hodgkin’s lymphoma (NHL). Clinical results were presented at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, California. In an oral presentation on the Phase I clinical trials results of JCAR015 in patients with B-cell NHL, Craig S. Sauter, M.D., of the Department of Medicine, Memorial Sloan Kettering Cancer Center, presented: At a median follow-up of 9 months (range 1-17.5), 6/6 (100%) patients with poor-risk, relapsed/refractory aggressive B cell NHL remain alive and in remission after treatment with high dose chemotherapy and autologous stem cell transplantation, followed by CD19-directed CAR T cell therapy. Two patients remain alive more than one year from treatment. One patient treated with 1 x107 CAR T/kg experienced severe CRS.
